Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Multi Units Luxembourg SICAV - Amundi STOXX Europe 600 Healthcare UCITS ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €132.13 |
52 Week High | €132.98 |
52 Week Low | €131.40 |
Beta | 0 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -0.56% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
CH5 | GB Capital Markets | GB Market | |
---|---|---|---|
7D | -0.3% | 2.1% | 0.4% |
1Y | n/a | 13.5% | 5.6% |
Return vs Industry: Insufficient data to determine how CH5 performed against the UK Capital Markets industry.
Return vs Market: Insufficient data to determine how CH5 performed against the UK Market.
Price Volatility
CH5 volatility | |
---|---|
CH5 Average Weekly Movement | n/a |
Capital Markets Industry Average Movement | 4.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.0% |
10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: CH5 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CH5's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | n/a | n/a | www.amundietf.lu/en/professional/products/equity/lyxor-stoxx-europe-600-healthcare-ucits-etf-dist/lu2082997516 |
Multi Units Luxembourg SICAV - Amundi STOXX Europe 600 Healthcare UCITS ETF is an exchange traded fund launched by Amundi Luxembourg S.A.. The fund is managed by Amundi Asset Management SAS. It invests in the public equity markets of Europe.
Multi Units Luxembourg SICAV - Amundi STOXX Europe 600 Healthcare UCITS ETF Fundamentals Summary
CH5 fundamental statistics | |
---|---|
Market cap | UK£733.74m |
Earnings (TTM) | UK£0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CH5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CH5 income statement (TTM) | |
---|---|
Revenue | UK£0 |
Cost of Revenue | UK£0 |
Gross Profit | UK£0 |
Other Expenses | UK£0 |
Earnings | UK£0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did CH5 perform over the long term?
See historical performance and comparison